dc.contributor.author |
Chiewchalermsri C. |
|
dc.contributor.author |
Sangkanjanavanich S. |
|
dc.contributor.author |
Pradubpongsa P. |
|
dc.contributor.author |
Mitthamsiri W. |
|
dc.contributor.author |
Jaisupa N. |
|
dc.contributor.author |
Jindarat S. |
|
dc.contributor.author |
Buranapraditkun S. |
|
dc.contributor.author |
Jacquet A. |
|
dc.contributor.author |
Sangasapaviliya A. |
|
dc.contributor.author |
Boonpiyathad T. |
|
dc.contributor.other |
Srinakharinwirot University |
|
dc.date.accessioned |
2023-11-15T02:08:12Z |
|
dc.date.available |
2023-11-15T02:08:12Z |
|
dc.date.issued |
2023 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160868794&doi=10.4168%2faair.2023.15.3.336&partnerID=40&md5=cbc1b52d659c695e8109c04770aaa4d6 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/29247 |
|
dc.description.abstract |
Purpose: Vitamin D (VitD) is an immunomodulatory molecule capable of alleviating allergic symptoms. However, the effectiveness of allergen-specific immunotherapy (AIT) is not commonly evidenced in the early build-up phase. The aim of the study was to determine the potential of VitD supplementation in this treatment phase. Methods: Thirty-four house dust mite (HDM)-allergic adult patients treated with subcutaneous AIT were randomized to receive VitD2 60,000 IU/week or placebo for 10 weeks and followed up for 10 weeks. The primary endpoints were the symptom-medication score (SMS) and the treatment response rate. The secondary endpoints were eosinophil count and levels of plasma IL-10, Der p 2-specific IgG4, and dysfunctional regulatory T (CRTH2+ Treg) cells. Results: Of 34 patients, 15 in each group completed the study. Patients with VitD deficiency receiving a VitD supplement showed significantly lower mean change SMS than the placebo group in weeks 10 (mean difference −54.54%, P = 0.007) and 20 (mean difference −42.69%, P = 0.04). The percentage of treatment responders reached 78% and 50% in the VitD and placebo groups, respectively, and the effect remained in week 20 (89% and 60%). No significant difference was observed for the tested immunological read-outs, with the exception of the frequency of CRTH2+ Treg cells, which was remarkably reduced in the VitD-treated patients. Moreover, improvement in SMS was correlated to the number of CRTH2+ Treg cells. Our in vitro experiment indicated that VitD downregulated activation markers, whereas it improved the function of CRTH2+ Treg cells. Conclusions: VitD supplementation in the build-up phase of AIT could relieve symptoms and decrease Treg cell dysfunction, especially in patients with VitD deficiency. Copyright © 2023 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease. |
|
dc.publisher |
Korean Academy of Asthma, Allergy and Clinical Immunology |
|
dc.subject |
alleric rhinitis |
|
dc.subject |
antigens, Dermatophagoides |
|
dc.subject |
immunologic desensitization |
|
dc.subject |
regulatory T-lymphocytes |
|
dc.subject |
treatment outcome |
|
dc.subject |
Vitamin D |
|
dc.title |
Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in the Build-up Phase of House Dust Mite-Specific Immunotherapy |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Allergy, Asthma and Immunology Research. Vol 15, No.3 (2023), p.336-347 |
|
dc.identifier.doi |
10.4168/aair.2023.15.3.336 |
|